Inclusion Criteria:  Men and women with a BMI of 25-39 kg/m2 Ages 45-64 years at randomization. Diagnosis of T2D classified based on physician diagnosis. No vulnerable populations (e.g., prisoners, pregnant, children) will be enrolled.  Exclusion Criteria:  Cardiovascular disease including myocardial infraction, heart failure, coronary artery disease, stroke History of chronic renal or hepatic disease Active cancer Autoimmune diseases Immunosuppressant therapy Hormone replacement therapy Excessive alcohol consumption (>14 drinks/week for men, >7 drinks/week for women) Current tobacco use Pregnancy (Premenopausal women will be required to complete a urine pregnancy test before participation) History of asthma or chronic obstructive pulmonary disease. History of allergic reaction to lactose or milk proteins Intranasal live attenuated influenza vaccine (LAIV) given within 2 weeks before zanamivir administration or a planned dose within 48 hours after zanamivir administration. Product insert states to avoid zanamivir administration with intranasal live attenuated influenza vaccine (LAIV).